Hostname: page-component-7b7567c8c-fvjsw Total loading time: 0 Render date: 2026-11-15T03:50:47.130Z Has data issue: false hasContentIssue false

Surrogate endpoints in cost-effectiveness analysis for use in health technology assessment – a qualitative analysis

Published online by Cambridge University Press:  07 August 2026

Laura Flight
Affiliation:
National Institute for Health and Care Excellence, UK
Fatima Salih*
Affiliation:
National Institute for Health and Care Excellence, UK
Shane D Collins
Affiliation:
National Institute for Health and Care Excellence, UK
Phyo Aung
Affiliation:
Department of Epidemiology and Preventive Medicine, Monash University, Australia
Michael Coory
Affiliation:
Mater Research Institute, Faculty of Medicine, University of Queensland, Australia
Daniel A Ollendorf
Affiliation:
Institute for Clinical and Economic Review , USA
Marina Richardson
Affiliation:
Institute for Clinical and Economic Review , USA
Zoe Garrett
Affiliation:
National Institute for Health and Care Excellence, UK
*
Corresponding author: Fatima Salih, Email: fatima.salih@nice.org.uk
Rights & Permissions [Opens in a new window]

Abstract

Objectives

The use of surrogate endpoints poses challenges to health technology assessment (HTA) agencies and payers when informing the clinical and cost-effectiveness of health technologies. Decision makers often need to make recommendations in the absence of well-established evidence on their validation, particularly when the surrogate endpoint is novel without clear links to the longer-term outcome. This study explored the guidance needs of HTA agencies and identified how they have considered and dealt with surrogate endpoints in cost-effectiveness analysis.

Methods

A qualitative study was used to explore the professional experiences of international HTA staff and their collaborators. Data were collected using three focus groups with 29 participants representing 20 HTA agencies or associated organizations. Framework analysis was used to identify themes from the transcripts.

Results

HTA agencies frequently see submissions featuring surrogate endpoints. Issues they face include definitional concerns, absent or weak evidentiary links, and resource-intensive validation methods. Versatile guidance that is mindful of these challenges, such as those faced with rare diseases, is required. This would help to clarify expectations and help ascertain the required information from industry for economic modeling, on how to present the uncertainty arising from surrogate endpoints, and how to appropriately report the findings.

Conclusions

Decision making using surrogate endpoints is a frequent and challenging problem faced by HTA agencies. These results provide the first-hand experiences and reflect the needs of HTA agencies globally. The resulting recommendations and considerations for the use of surrogate endpoints in economic modeling should benefit HTA agencies moving forward.

Information

Type
Method
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2026. Published by Cambridge University Press
Figure 0

Table 1.Summary of the number of participants and agencies and associated organizations represented in the three focus groupsTable 1. long description.

Figure 1

Table 2.Focus group recommendations for future use of surrogate endpoints in economic modeling for HTA used to inform the findings of the wider project (4)Table 2. long description.